CatalystWireBeta

Commercial Update

In brief · summary, not quotable

Invention Evaluator Platform soft launch successful; full commercial launch December 2026, management estimates US$50m addressable market.

  • Pilot accounts identified 17
  • Potential annual subscription value from pilot accounts US$170,000
  • Estimated global addressable market for subscription platform US$50 million per annum
  • Sales pipeline from potential customers US$1.0 million
  • Historical customer base approximately 300 customers
  • Expected cash burn reduction in 2027 approximately 40%
Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your GNIP notes

GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, provides an update on the soft launch of its Invention Evaluator Platform (the “Platform”) as announced on the 19 October 2026.

Successful Soft Launch

Several customers have now successfully trialled the Platform and initial feedback has been positive, with customers preferring the Platform’s new features and its streamlined, action-oriented approach to managing and prioritising technologies.

During the trial, the Company identified 17 pilot accounts across several international markets and has already begun initial commercial discussions about migrating them to the new Platform including a significant customer from 2025, who has already agreed to initiate the migration plan as an early adopter.

Based on this early feedback, management believes the pilot accounts alone could represent a potential annual subscription value of around US$170,000 in aggregate*.

Full Commercial Launch Remains on Track

The full commercial launch of the subscription-based Invention Evaluation Platform remains on track for December 2026.

Following the full commercial launch, the Company intends to target its historical customer base of approximately 300 customers presenting them the migration path to the subscription model.

Given the early feedback and ongoing customer conversations, management now estimates a global total addressable market of approximately US$50million per annum*, before additional services, for the new subscription Invention Evaluation Platform.

Continued commercial progress and sales pipeline

GenIP continues to secure orders for its existing services from new and existing customers, including universities in Chile and Brazil, a Brazilian technology company and a Spanish university-industry collaboration network:

Following the appointment of a sales representative in Chile, GenIP has secured three new customers and reactivated two historical customer relationships across South America.

Increased broader client adoption and repeat usage across academia, government innovation bodies and corporate Research and Development departments, diversifying and strengthening the customer base.

Expanded commercial coverage across Asia and Latin America through regional business development appointments.

There is also growing engagement from commercial and corporate customers, including opportunities with organisations associated with Saudi Aramco and several advanced proposal discussions with Amazon Web Services (AWS) in Brazil.

In aggregate, management estimate these potential customers represent a sales pipeline of approximately US$1.0 million*.

Outlook

GenIP is entering a new commercial phase, with early positive interest from customers for the Invention Evaluator Platform with its more efficient operating model.

The Company’s immediate priorities are now to convert the significant and increasing sales pipeline into confirmed orders, secure its first paid platform subscriptions and demonstrate improved delivery margins.

The Board therefore remains confident the business will continue to trade in-line with management expectations for the remainder of 2026 and reduce cash burn by approximately 40% in 2027, as the businesses transitions onto a stronger foundation with significant levels of recurring revenue.

* Potential value is not contracted ARR or a revenue forecast.

GenIP plc Melissa Cruz, CEOVia Walbrook PR
Beaumont Cornish Limited (Nominated Adviser) Roland Cornish / Asia Szusciak / Andrew PriceTel: +44 (0) 20 7628 3396
AlbR Capital Limited (Joint Broker) Colin Rowbury / Jon BellissTel: +44 (0) 20 7399 9427 cr@albrcapital.com / Jb@albrcapital.com
Walbrook PR (Financial PR) Alice Woodings William TurnerGenIP@walbrookpr.com Tel: +44 (0) 7407 804 654 Tel: +44 (0) 7407 020 470
focusIR (Investor Relations) Kat Perez Dr Paul CorneliusGenIP@focusIR.com Tel: +44 (0) 20 4570 2234 Tel: +44 (0) 20 4570 2246
Service Offerings
GenIP operates through two synergistic service lines:
ServiceDescriptionValue Proposition
Invention Intelligence Product SuiteAI-powered market intelligence reports assessing the commercial potential of emerging technologiesEnables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy
IP Commercialisation ServicesEnd-to-end engagement to help research organisations commercialise innovationsProvides cost-effective, broad support to achieve our clients' strategic objectives

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

Organic Expansion: Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

Service Deepening: Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

Strategic Acquisitions: Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note